HNRNPC Succinylation Influences the Neurodegeneration of Alzheimer's Disease Through YME1L1-Mediated Mitochondrial Metabolism.

Overview

1. Department of Neurology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China
2. Department of Neurology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China

Abstract

Mitochondrial dysfunction and abnormal energy metabolism are important pathological features of Alzheimer's disease (AD). This study investigates how mitochondrial protease YME1L1 affects mitochondrial function and its upstream regulation in the pathogenesis of AD. The AD model was established by using APP/PS1 transgenic mice, primary neurons treated with Aβ1‐42, and HT22 cells. The silencing of YME1L1 was achieved to evaluate its effects on mitochondrial function and OPA1 protein hydrolysis. RIP‐qPCR and RNA pull‐down test were used to evaluate the interaction between HNRNPC and YME1L1 mRNA. The protein succinylation level was detected by proteomic analysis of succinylation, and co‐immunoprecipitation (Co‐IP) was used to verify the succinylation of HNRNPC. Cognitive ability was tested by behavioral tests, including the Morris water maze, Y‐maze, object recognition test, and olfactory test. Finally, the therapeutic potential of SIRT5 was studied by an overexpression experiment in an AD model. YME1L1 was significantly upregulated in the AD model, which promoted mitochondrial dysfunction and neuronal damage through OPA1 hydrolysis. HNRNPC enhances the stability of YME1L1 mRNA through an m6A‐dependent mechanism, while its own K50 succinylation enhances the stability of HNRNPC by competitively inhibiting TRIM25‐mediated ubiquitination, further amplifying the expression of YME1L1. SIRT5 downregulation in AD elevated HNRNPC succinylation levels. SIRT5 overexpression promoted HNRNPC desuccinylation, reduced YME1L1 expression, restored mitochondrial function, and ameliorated Aβ deposition and cognitive deficits in AD mice. The SIRT5‐HNRNPC‐YME1L1 axis contributes to AD pathogenesis by disrupting OPA1 proteolysis and mitochondrial dynamics. Targeting HNRNPC succinylation represents a promising therapeutic strategy for AD.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• geo:GSE48350 — at NCBI GEO; found in the text, “YME1L1 Is Highly Expressed in AD Models and…”

Data Availability Statement

The datasets generated during and analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 5 keywords, 10 MeSH terms, 1 funder, 51 references.

Cite

This paper

Li, X., Yang, F., Jiang, Y., Zhao, F., & Liu, F. (2026). HNRNPC Succinylation Influences the Neurodegeneration of Alzheimer's Disease Through YME1L1-Mediated Mitochondrial Metabolism. Aging cell, 25(8), e70646. https://doi.org/10.1111/acel.70646

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1016/j.apsb.2026.07.009

Neutrophil-mediated BDNF delivery for the treatment of moderate to severe Alzheimer's disease.

Journal: Acta pharmaceutica Sinica. B

In common: NCBI GEO GSE48350, Alzheimer's / dementia, mouse

[2] doi:10.1186/s40035-026-00567-z

Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer's disease.

Journal: Translational neurodegeneration

In common: Alzheimer's / dementia, mouse, cellular / molecular, 1 reference

[3] doi:10.1126/sciadv.adz0887

Neuronal YTHDF2 suppresses innate immune activation in Aβ pathology by promoting m<sup>6</sup>A-dependent decay of cytosolic mitochondrial mRNAs.

Journal: Science advances

In common: Alzheimer's / dementia, mouse, cellular / molecular, 1 reference

[4] doi:10.1002/cns.71021

Multilayer Proteome and Metabolome-Based Validation Uncovers Combined Regulatory Roles and Predictive Values of 6 RNA Modifications and Cellular Senescence in Alzheimer's Disease.

Journal: CNS neuroscience & therapeutics

In common: Alzheimer's / dementia, cellular / molecular, 1 reference

[5] doi:10.1038/s44318-026-00818-9 [code]

FAM134B-mediated ER-phagy degrades APP and suppresses Alzheimer's disease pathology.

Journal: The EMBO journal

In common: Alzheimer's / dementia, mouse, cellular / molecular, 1 reference

[6] doi:10.1186/s13195-026-02018-3

Impact of Apolipoprotein E4 on blood-brain barrier integrity in target replacement murine models: a systematic review and meta-analysis.

Journal: Alzheimer's research & therapy

In common: Alzheimer's / dementia, mouse, 1 reference

[7] doi:10.1111/acel.70616

Transcriptomic Evidence of Mitochondrial Double-Stranded RNA Accumulation in Brain Aging and Alzheimer's Disease.

Journal: Aging cell

In common: Alzheimer's / dementia, cellular / molecular, 1 reference

[8] doi:10.34133/csbj.0134 [code]

Integrated Multi-Tissue Transcriptomics Reveals Antagonistic Pleiotropy in Aging and Alzheimer's Disease.

Journal: Computational and structural biotechnology journal

In common: Alzheimer's / dementia, cellular / molecular, 1 reference

[9] doi:10.1007/s12035-026-05973-y

Integrative Transcriptomic, Network, and Machine Learning Analyses Identify Genistein and Resveratrol-Associated Therapeutic Targets in Alzheimer's Disease.

Journal: Molecular neurobiology

In common: Alzheimer's / dementia, cellular / molecular, 1 reference

[10] doi:10.3389/fnagi.2026.1839445 [code]

The molecular mechanisms of Guizhi Fuling Pills in ameliorating Alzheimer's disease-like cognitive impairment: insights from transcriptomics, metabolomics, and gut microbiome.

Journal: Frontiers in aging neuroscience

In common: Alzheimer's / dementia, mouse, cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.